Abstract:Auditory neuropathy spectrum disorder (ANSD) is a hearing impairment involving disruptions to inner hair cells (IHCs), ribbon synapses, spiral ganglion neurons (SGNs), and/or the auditory nerve itself. The outcomes of cochlear implants (CI) for ANSD are variable and dependent on the location of lesion sites. Discovering a potential therapeutic agent for ANSD remains an urgent requirement. Here, 293T stable transfection cell lines and patient induced pluripotent stem cells (iPSCs)-derived auditory neurons carrying the apoptosis inducing factor (AIF) p.R422Q variant were used to pursue a therapeutic regent for ANSD. Nicotinamide adenine dinucleotide (NADH) is a main electron donor in the electron transport chain (ETC). In 293T stable transfection cells with the p.R422Q variant, NADH treatment improved AIF dimerization, rescued mitochondrial dysfunctions, and decreased cell apoptosis. The effects of NADH were further confirmed in patient iPSCs-derived neurons. The relative level of AIF dimers was increased to 150.7 % (P = 0.026) from 59.2 % in patient-neurons upon NADH treatment. Such increased AIF dimerization promoted the mitochondrial import of coiled-coil-helix-coiled-coil-helix domain-containing protein 4 (CHCHD4), which further restored mitochondrial functions. Similarly, the content of mitochondrial calcium (mCa2+) was downregulated from 136.7 % to 102.3 % (P = 0.0024) in patient-neurons upon NADH treatment. Such decreased mCa2+ levels inhibited calpain activity, ultimately reducing the percentage of apoptotic cells from 30.5 % to 21.1 % (P = 0.021). We also compared the therapeutic effects of gene correction and NADH treatment on hereditary ANSD. NADH treatment had comparable restorative effects on functions of ANSD patient-specific cells to that of gene correction. Our findings offer evidence of the molecular mechanisms of ANSD and introduce NADH as a potential therapeutic agent for ANSD therapy.

[Therapeutic potential of NADH: in neurodegenerative diseases characterizde by mitochondrial dysfunction]

Nicotinamide Forestalls Pathology and Cognitive Decline in Alzheimer Mice: Evidence for Improved Neuronal Bioenergetics and Autophagy Procession

NAD+ in Alzheimer’s Disease: Molecular Mechanisms and Systematic Therapeutic Evidence Obtained in vivo

NAD+ Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications

NADH: the redox sensor in aging-related disorders.

Nad(+) Metabolism and Nad(+)-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases

Pharmacology and Potential Implications of Nicotinamide Adenine Dinucleotide Precursors.

Therapeutic effect of nicotinamide mononucleotide on Alzheimer's disease through activating autophagy and anti-oxidative stress

Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD Plus Metabolism

NAD(H) in mitochondrial energy transduction: implications for health and disease

Therapeutic Effect of Nicotinamide Mononucleotide on Alzheimer’s Disease Through Activating Autophagy and Anti-Oxidative Stress

NAD<SUP>+</SUP> and cardiovascular diseases

Potential Therapeutic Interventions Targeting NAD+ Metabolism for ALS

NAD + -boosting agent nicotinamide mononucleotide potently improves mitochondria stress response in Alzheimer's disease via ATF4-dependent mitochondrial UPR

Implications of altered NAD metabolism in metabolic disorders

NADH improves AIF dimerization and inhibits apoptosis in iPSCs-derived neurons from patients with auditory neuropathy spectrum disorder

Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule

Nad(+)/Nadh Metabolism And Nad(+)-Dependent Enzymes In Cell Death And Ischemic Brain Injury: Current Advances And Therapeutic Implications

Protective Effects of Β- Nicotinamide Adenine Dinucleotide Against Motor Deficits and Dopaminergic Neuronal Damage in a Mouse Model of Parkinson's Disease